Shareholders are very likely to turn down the Michael Saylor pitch, Polymarket bettors are predicting. …
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage …